Arya M. Sharma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Arya M. Sharma has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Tobias Pischon
Molecular Epidemiology Research Group, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
4 shared publications Armin Distler
Department of Internal Medicine Division of Endocrinology and Nephrology, Universitätsklinikum Benjamin Franklin , Berlin , Germany
2 shared publicationsHans-Christian Koennecke
Department of Neurology, Universitätsklinikum Benjamin Franklin , Berlin , Germany
2 shared publicationsHenriette Hohenbleicher
Department of Internal Medicine, Division of Endocrinology and Nephrology, Universitätsklinikum Benjamin Franklin, Berlin, Germany
2 shared publicationsIris Kunz
From the Franz Volhard Clinic and Max Delbrück Center for Molecular Medicine, Medical Faculty of the Charité, Humboldt University, Berlin, Germany
2 shared publicationsJens Offermann
Department of Internal Medicine Division of Endocrinology and Nephrology, Universitätsklinikum Benjamin Franklin , Berlin , Germany
2 shared publications
Latest Publications
- Open Access
- 1 January 2003
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 16 (1) , 98-100
Effect of forced titration of nebivolol on response rate in obese hypertensive patients.
Although hypertension is a common finding in obesity, current guidelines do not provide specific recommendations for the treatment of obesity hypertension that go beyond the rather general recommendation to reduce body weight.1 Furthermore, response rates to antihypertensive treatment are notoriously low in overweight or obese patients. For example, a study by Lloyd-Jones et al reported that obese patients have a 50% increased risk for lacking blood pressure (BP) control on antihypertensive treatment compared to lean patients.2
- 1 January 2003
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 16 (1) , 98-100
Open AccessEffect of forced titration of nebivolol on response rate in obese hypertensive patients.
Although hypertension is a common finding in obesity, current guidelines do not provide specific recommendations for the treatment of obesity hypertension that go beyond the rather general recommendation to reduce body weight.1 Furthermore, response rates to antihypertensive treatment are notoriously low in overweight or obese patients. For example, a study by Lloyd-Jones et al reported that obese patients have a 50% increased risk for lacking blood pressure (BP) control on antihypertensive treatment compared to lean patients.2
- 1 September 2002
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 20 (9) , 1873-1878
Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension
To investigate the effects of long-term weight management with orlistat on blood pressure in obese hypertensive patients. A meta-analysis of data from five multicenter, randomized, placebo-controlled studies, conducted in Europe and the USA, was performed. Obese adults [body mass index (BMI) 28–43 kg/m2] with uncontrolled diastolic hypertension or isolated systolic hypertension (ISH) were eligible for inclusion. Following a 4-week placebo lead-in period, patients were randomized to orlistat 120 mg or placebo three times daily, in conjunction with a mildly reduced calorie diet for 1 year. Change in body weight was the primary efficacy parameter. Blood pressure, heart rate and systolic workload were assessed as secondary efficacy parameters. A total of 628 patients were included in the intent-to-treat (ITT) analysis. After 56 weeks, orlistat-treated patients had lost significantly more body weight than placebo recipients (8.0 versus 4.0%;P < 0.001). Among patients with ISH, mean systolic pressure was reduced to a significantly greater degree after 1 year with orlistat compared to placebo (−9.4 versus −4.6 mmHg;P = 0.022). Similarly, reductions in mean diastolic pressure in patients with diastolic hypertension were greater with orlistat than with placebo (−7.7 versus −5.6 mmHg;P = 0.017). Weight loss of ≥ 10% was associated with significant reductions in blood pressure, heart rate and systolic workload. Orlistat promotes clinically meaningful weight loss that is associated with significant reductions in blood pressure and heart rate, and may therefore have a role in the management of hypertension in overweight and obese patients.
- 1 September 2002
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 20 (9) , 1873-1878
Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension
To investigate the effects of long-term weight management with orlistat on blood pressure in obese hypertensive patients. A meta-analysis of data from five multicenter, randomized, placebo-controlled studies, conducted in Europe and the USA, was performed. Obese adults [body mass index (BMI) 28–43 kg/m2] with uncontrolled diastolic hypertension or isolated systolic hypertension (ISH) were eligible for inclusion. Following a 4-week placebo lead-in period, patients were randomized to orlistat 120 mg or placebo three times daily, in conjunction with a mildly reduced calorie diet for 1 year. Change in body weight was the primary efficacy parameter. Blood pressure, heart rate and systolic workload were assessed as secondary efficacy parameters. A total of 628 patients were included in the intent-to-treat (ITT) analysis. After 56 weeks, orlistat-treated patients had lost significantly more body weight than placebo recipients (8.0 versus 4.0%;P < 0.001). Among patients with ISH, mean systolic pressure was reduced to a significantly greater degree after 1 year with orlistat compared to placebo (−9.4 versus −4.6 mmHg;P = 0.022). Similarly, reductions in mean diastolic pressure in patients with diastolic hypertension were greater with orlistat than with placebo (−7.7 versus −5.6 mmHg;P = 0.017). Weight loss of ≥ 10% was associated with significant reductions in blood pressure, heart rate and systolic workload. Orlistat promotes clinically meaningful weight loss that is associated with significant reductions in blood pressure and heart rate, and may therefore have a role in the management of hypertension in overweight and obese patients.
- Open Access
- 1 July 2002
- Published by Wiley in The FASEB Journal
- Vol. 16 (9) , 1057-1063
Periadventitial fat releases a vascular relaxing factor
Virtually all blood vessels are surrounded by adventitial fat. Adipocytes produce a host of vasoactive substances that may influence vascular contraction. We tested whether or not perivascular adipose tissue modulates contraction of aortic ring preparations. We studied aortic rings surrounded by periadventitial adipose tissue from adult Sprague‐Dawley rats. At a maximum concentration of 300 nM angiotensin II, 6.5 μM serotonin, and 5 μM phenyleph‐rine, the contractile response of intact rings was 95%, 80%, and 30% lower than that of vessels without periadventitial fat. The anticontractile effect of periad‐ventitial fat was reduced by inhibition of ATP‐dependent K + channels with glibenclamide (3 μM) and by the tyrosine kinase inhibitor genistein (10 μM). Blocking NOS, cyclo‐oxygenase, cytochrome P450, or adenosine receptors did not restore the vascular response in intact vessels. The anticontractile effect of perivascular fat was present in Zucker fa/fa rats, suggesting that leptin receptors were not responsible. Transferring the bath solution from intact vessels, isolated periadventitial tissue, and cultured rat adipocytes to precontracted vessels lacking periadventitial fat resulted in a rapid relaxation. We suggest that perivascular adventitial adipose tissue releases a transferable adventitium‐derived relaxing factor that acts by tyrosine kinase‐dependent activation of K + channels in vascular smooth muscle cells..—Löhn, M., Dubrovska, G., Lauterbach, B., Luft, F. C., Gollasch, M., Sharma, A. M. Periadventitial fat releases a vascular relaxing factor. FASEB J. 16, 1057–1063 (2002)
- 1 July 2002
- Published by Wiley in The FASEB Journal
- Vol. 16 (9) , 1057-1063
Open AccessPeriadventitial fat releases a vascular relaxing factor
Virtually all blood vessels are surrounded by adventitial fat. Adipocytes produce a host of vasoactive substances that may influence vascular contraction. We tested whether or not perivascular adipose tissue modulates contraction of aortic ring preparations. We studied aortic rings surrounded by periadventitial adipose tissue from adult Sprague‐Dawley rats. At a maximum concentration of 300 nM angiotensin II, 6.5 μM serotonin, and 5 μM phenyleph‐rine, the contractile response of intact rings was 95%, 80%, and 30% lower than that of vessels without periadventitial fat. The anticontractile effect of periad‐ventitial fat was reduced by inhibition of ATP‐dependent K + channels with glibenclamide (3 μM) and by the tyrosine kinase inhibitor genistein (10 μM). Blocking NOS, cyclo‐oxygenase, cytochrome P450, or adenosine receptors did not restore the vascular response in intact vessels. The anticontractile effect of perivascular fat was present in Zucker fa/fa rats, suggesting that leptin receptors were not responsible. Transferring the bath solution from intact vessels, isolated periadventitial tissue, and cultured rat adipocytes to precontracted vessels lacking periadventitial fat resulted in a rapid relaxation. We suggest that perivascular adventitial adipose tissue releases a transferable adventitium‐derived relaxing factor that acts by tyrosine kinase‐dependent activation of K + channels in vascular smooth muscle cells..—Löhn, M., Dubrovska, G., Lauterbach, B., Luft, F. C., Gollasch, M., Sharma, A. M. Periadventitial fat releases a vascular relaxing factor. FASEB J. 16, 1057–1063 (2002)
- Open Access
- 1 February 2002
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 15 (2) , 119-124
Neurovascular contact and blood pressure response in young, healthy, normotensive men
Neurovascular contact (NVC) of the left rostral ventrolateral medulla has been implicated in the pathogenesis of “essential” hypertension, and recent studies suggest that this anomaly may be genetically determined. We therefore assessed the prevalence of this vascular anomaly in young normotensive volunteers. We also studied blood pressure, heart rate reactivity, and changes in baroreflex sensitivity in response to mental and physical stress in a subset of subjects with positive and negative brainstem findings. Magnetic resonance imaging of the brainstem was performed in 113 young (aged 25 ± 8 years), normotensive male volunteers. Baroreflex sensitivity was then assessed in 13 subjects with positive brainstem findings and 20 subjects with negative findings. Left-sided NVC was found in 19 subjects. Blood pressure levels, heart rate, and baroreflex sensitivity were similar in all groups. However, modulation of baroreflex sensitivity was reduced under mental and physical stress in subjects with a positive finding for NVC. Subjects with a positive finding also had a significantly lower body mass index than those with a negative finding. Left-sided NVC is present in approximately one-fifth of young normotensive men, and may modulate the baroreceptor reflex under stress in these individuals.
- 1 February 2002
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 15 (2) , 119-124
Open AccessNeurovascular contact and blood pressure response in young, healthy, normotensive men
Neurovascular contact (NVC) of the left rostral ventrolateral medulla has been implicated in the pathogenesis of “essential” hypertension, and recent studies suggest that this anomaly may be genetically determined. We therefore assessed the prevalence of this vascular anomaly in young normotensive volunteers. We also studied blood pressure, heart rate reactivity, and changes in baroreflex sensitivity in response to mental and physical stress in a subset of subjects with positive and negative brainstem findings. Magnetic resonance imaging of the brainstem was performed in 113 young (aged 25 ± 8 years), normotensive male volunteers. Baroreflex sensitivity was then assessed in 13 subjects with positive brainstem findings and 20 subjects with negative findings. Left-sided NVC was found in 19 subjects. Blood pressure levels, heart rate, and baroreflex sensitivity were similar in all groups. However, modulation of baroreflex sensitivity was reduced under mental and physical stress in subjects with a positive finding for NVC. Subjects with a positive finding also had a significantly lower body mass index than those with a negative finding. Left-sided NVC is present in approximately one-fifth of young normotensive men, and may modulate the baroreceptor reflex under stress in these individuals.
- 29 November 2001
- Vol. 143 (48) , 34-8
[Lowering blood pressure in obese hypertensive patients. Which antihypertensive drugs are suitable].
Current guidelines in the treatment of arterial hypertension do not recommend differential treatment of obesity-associated hypertension. Since optimal blood pressure control in most obese hypertensives requires a combination of blood pressure-lowering substances, careful consideration of the choice of treatment is of particular importance. On the basis of their favorable metabolic properties, ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, and low-dose diuretics, should be preferentially employed in the obese. Beta-blockers should not be given to young obese patients with uncomplicated hypertension. Before definitive pronouncements on what constitutes optimal treatment of obese patients can be made, the results of studies looking at hard end points must be available.
- 29 November 2001
- Vol. 143 (48) , 34-8
[Lowering blood pressure in obese hypertensive patients. Which antihypertensive drugs are suitable].
Current guidelines in the treatment of arterial hypertension do not recommend differential treatment of obesity-associated hypertension. Since optimal blood pressure control in most obese hypertensives requires a combination of blood pressure-lowering substances, careful consideration of the choice of treatment is of particular importance. On the basis of their favorable metabolic properties, ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, and low-dose diuretics, should be preferentially employed in the obese. Beta-blockers should not be given to young obese patients with uncomplicated hypertension. Before definitive pronouncements on what constitutes optimal treatment of obese patients can be made, the results of studies looking at hard end points must be available.
- 1 April 2001
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 19 (4) , 667-674
Choice of drug treatment for obesity-related hypertension: where is the evidence?
Hypertension and obesity are common medical conditions independently associated with increased cardiovascular risk. Many large epidemiological studies have demonstrated associations between body mass index and blood pressure, and there is evidence to suggest that obesity is a causal factor in the development of hypertension in obese individuals. Consequently, all hypertension management guidelines consider weight reduction as a first step in the management of increased blood pressure in obese individuals. Weight reduction may be achieved by behaviour modification, diet and exercise, or by the use of anti-obesity medications. However, the long-term outcomes of weight management programmes for obesity are generally poor, and most hypertensive patients will require antihypertensive drug treatment. Some classes of antihypertensive agents may have potentially unwanted effects on some of the metabolic and haemodynamic abnormalities that link obesity and hypertension, yet most hypertension guidelines fail to provide specific advice on the pharmacological management of obese patients. This may be because there are currently no studies examining the efficacy of specific antihypertensive agents in reducing mortality in obese hypertensive patients. This paper reviews the theoretical reasons for the differential use of the major classes of antihypertensive agents in the pharmacological management of obesity-related hypertension and also considers the potential role of anti-obesity agents.
- 1 April 2001
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 19 (4) , 667-674
Choice of drug treatment for obesity-related hypertension: where is the evidence?
Hypertension and obesity are common medical conditions independently associated with increased cardiovascular risk. Many large epidemiological studies have demonstrated associations between body mass index and blood pressure, and there is evidence to suggest that obesity is a causal factor in the development of hypertension in obese individuals. Consequently, all hypertension management guidelines consider weight reduction as a first step in the management of increased blood pressure in obese individuals. Weight reduction may be achieved by behaviour modification, diet and exercise, or by the use of anti-obesity medications. However, the long-term outcomes of weight management programmes for obesity are generally poor, and most hypertensive patients will require antihypertensive drug treatment. Some classes of antihypertensive agents may have potentially unwanted effects on some of the metabolic and haemodynamic abnormalities that link obesity and hypertension, yet most hypertension guidelines fail to provide specific advice on the pharmacological management of obese patients. This may be because there are currently no studies examining the efficacy of specific antihypertensive agents in reducing mortality in obese hypertensive patients. This paper reviews the theoretical reasons for the differential use of the major classes of antihypertensive agents in the pharmacological management of obesity-related hypertension and also considers the potential role of anti-obesity agents.
- 1 February 2001
- Published by Wolters Kluwer Health in Hypertension
- Vol. 37 (2) , 250-254
Hypothesis: β-Adrenergic Receptor Blockers and Weight Gain
One of the arguments put forward against the primary use of β-blockers has been concern about adverse metabolic effects, such as unfavorable effects on lipids or insulin sensitivity. Another less-appreciated potential drawback is their propensity to cause weight gain in some patients. In 8 evaluable prospective randomized controlled trials that lasted ≥6 months, body weight was higher in the β-blocker than in the control group at the end of the study. The median difference in body weight was 1.2 kg (range −0.4 to 3.5 kg). A regression analysis suggested that β-blockers were associated with an initial weight gain during the first few months. Thereafter, no further weight gain compared with controls was apparent. There was no relationship between demographic characteristics and changes in body weight. Based on these observations, the first-line use of β-blockers in obese hypertensive patients should be reviewed. Obesity management in overweight hypertensive patients may be more difficult in the face of β-blocker treatment.
- 1 February 2001
- Published by Wolters Kluwer Health in Hypertension
- Vol. 37 (2) , 250-254
Hypothesis: β-Adrenergic Receptor Blockers and Weight Gain
One of the arguments put forward against the primary use of β-blockers has been concern about adverse metabolic effects, such as unfavorable effects on lipids or insulin sensitivity. Another less-appreciated potential drawback is their propensity to cause weight gain in some patients. In 8 evaluable prospective randomized controlled trials that lasted ≥6 months, body weight was higher in the β-blocker than in the control group at the end of the study. The median difference in body weight was 1.2 kg (range −0.4 to 3.5 kg). A regression analysis suggested that β-blockers were associated with an initial weight gain during the first few months. Thereafter, no further weight gain compared with controls was apparent. There was no relationship between demographic characteristics and changes in body weight. Based on these observations, the first-line use of β-blockers in obese hypertensive patients should be reviewed. Obesity management in overweight hypertensive patients may be more difficult in the face of β-blocker treatment.
- 1 January 2001
- Published by Wolters Kluwer Health in Hypertension
- Vol. 37 (1) , 176-181
Neurovascular Contact of Cranial Nerve IX and X Root-Entry Zone in Hypertensive Patients
—Neurovascular contact of the left rostral ventrolateral medulla has been implicated in the pathogenesis of “essential” hypertension, and recent intervention studies suggest that surgical decompression of the ventrolateral medulla lowers blood pressure in these patients. We assessed the prevalence of this vascular anomaly in patients with essential hypertension by using an advanced MRI technique. We performed MRI of the brain stem in 125 hypertensive patients and in 105 age-matched, sex-matched, and body mass index–matched normotensive control subjects. Imaging of the root-entry zone of cranial nerves IX and X was performed by combining a high-resolution 3D constructive interference in steady-state sequence with a flow-sensitive time-of-flight technique, and images were independently assessed by 4 readers using predefined criteria. Left-sided neurovascular contact was found in 23% of the hypertensive patients and in 16% of the normotensive individuals ( P =0.12). Blood pressure level, heart rate, and number of antihypertensive medications in treated hypertensive patients were similar among patients with positive, borderline, and negative brain stem findings. Our findings cast doubt on the importance of left-sided neurovascular contact as a frequent cause of essential hypertension or as a major factor determining the severity of hypertension in patients with this anomaly.
- 1 January 2001
- Published by Wolters Kluwer Health in Hypertension
- Vol. 37 (1) , 176-181
Neurovascular Contact of Cranial Nerve IX and X Root-Entry Zone in Hypertensive Patients
—Neurovascular contact of the left rostral ventrolateral medulla has been implicated in the pathogenesis of “essential” hypertension, and recent intervention studies suggest that surgical decompression of the ventrolateral medulla lowers blood pressure in these patients. We assessed the prevalence of this vascular anomaly in patients with essential hypertension by using an advanced MRI technique. We performed MRI of the brain stem in 125 hypertensive patients and in 105 age-matched, sex-matched, and body mass index–matched normotensive control subjects. Imaging of the root-entry zone of cranial nerves IX and X was performed by combining a high-resolution 3D constructive interference in steady-state sequence with a flow-sensitive time-of-flight technique, and images were independently assessed by 4 readers using predefined criteria. Left-sided neurovascular contact was found in 23% of the hypertensive patients and in 16% of the normotensive individuals ( P =0.12). Blood pressure level, heart rate, and number of antihypertensive medications in treated hypertensive patients were similar among patients with positive, borderline, and negative brain stem findings. Our findings cast doubt on the importance of left-sided neurovascular contact as a frequent cause of essential hypertension or as a major factor determining the severity of hypertension in patients with this anomaly.
- 1 July 2000
- Published by Wolters Kluwer Health in Hypertension
- Vol. 36 (1) , 26-32
Resting Metabolic Rate and Substrate Use in Obesity Hypertension
—There is substantial evidence that obesity is a prime risk factor for the development of hypertension. Although hyperinsulinemia and an increased activity of the sympathetic nervous system have been implicated in the pathogenesis of “obesity hypertension,” their effects on energy metabolism have not been studied thus far. In the present study, we therefore examined resting metabolic rate (RMR) and basal substrate oxidation in subjects with obesity and obesity-related hypertension. A total of 166 subjects were characterized for RMR and basal substrate use through indirect calorimetry. Blood pressure was measured at rest and with 24-hour ambulatory monitoring. Blood samples were collected for the measurement of plasma catecholamines, leptin, and the insulin response to an oral glucose load. In our study population, 116 subjects were defined as hypertensive and 91 were defined as obese. Hypertensive patients under β-adrenergic blockade (n=42) had a significantly lower RMR than did patients without β-blockade ( P P P P P <0.01). Together, these findings are compatible with the idea that chronic neurogenic and metabolic adaptations related to obesity may play a role in the development of obesity hypertension in susceptible individuals.
- 1 July 2000
- Published by Wolters Kluwer Health in Hypertension
- Vol. 36 (1) , 26-32
Resting Metabolic Rate and Substrate Use in Obesity Hypertension
—There is substantial evidence that obesity is a prime risk factor for the development of hypertension. Although hyperinsulinemia and an increased activity of the sympathetic nervous system have been implicated in the pathogenesis of “obesity hypertension,” their effects on energy metabolism have not been studied thus far. In the present study, we therefore examined resting metabolic rate (RMR) and basal substrate oxidation in subjects with obesity and obesity-related hypertension. A total of 166 subjects were characterized for RMR and basal substrate use through indirect calorimetry. Blood pressure was measured at rest and with 24-hour ambulatory monitoring. Blood samples were collected for the measurement of plasma catecholamines, leptin, and the insulin response to an oral glucose load. In our study population, 116 subjects were defined as hypertensive and 91 were defined as obese. Hypertensive patients under β-adrenergic blockade (n=42) had a significantly lower RMR than did patients without β-blockade ( P P P P P <0.01). Together, these findings are compatible with the idea that chronic neurogenic and metabolic adaptations related to obesity may play a role in the development of obesity hypertension in susceptible individuals.
- 1 January 2000
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 32 (11/12) , 485-499
Role of Adipose Tissue for Cardiovascular-Renal Regulation in Health and Disease
Obesity is associated with profound alterations of the cardiovascular system including an increase in systemic blood pressure. Several vasoactive factors, including non-esterified fatty acids, angiotensin II, prostaglandins, and nitric oxide are known to be produced by adipose tissue, and are therefore of particular interest regarding their potential role for the regulation of vascular tone and structure. In addition, central nervous system actions of the adipose tissue-derived hormone leptin may contribute to increased sympathetic nervous system activity that is typically found in obesity. Enhanced leptin-driven renal sympathetic out-flow, in combination with low atrial natriuretic peptide plasma levels possibly due to over-expression of the natriuretic peptide clearance receptor in adipocytes, may enhance sodium retention and volume expansion, both key features in the pathophysiology of obesity-associated hypertension. In this review, we discuss these and other possible contributions of adipose tissue to the regulation of cardiovascular-renal function and speculate on the role of adipose tissue for the development of obesity-associated hypertension.
- 1 January 2000
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 32 (11/12) , 485-499
Role of Adipose Tissue for Cardiovascular-Renal Regulation in Health and Disease
Obesity is associated with profound alterations of the cardiovascular system including an increase in systemic blood pressure. Several vasoactive factors, including non-esterified fatty acids, angiotensin II, prostaglandins, and nitric oxide are known to be produced by adipose tissue, and are therefore of particular interest regarding their potential role for the regulation of vascular tone and structure. In addition, central nervous system actions of the adipose tissue-derived hormone leptin may contribute to increased sympathetic nervous system activity that is typically found in obesity. Enhanced leptin-driven renal sympathetic out-flow, in combination with low atrial natriuretic peptide plasma levels possibly due to over-expression of the natriuretic peptide clearance receptor in adipocytes, may enhance sodium retention and volume expansion, both key features in the pathophysiology of obesity-associated hypertension. In this review, we discuss these and other possible contributions of adipose tissue to the regulation of cardiovascular-renal function and speculate on the role of adipose tissue for the development of obesity-associated hypertension.